rank,company,total_score,fit_score,urgency_score,access_score,trial_count,best_fit_trial_title,best_fit_trial_status,best_fit_trial_phases,best_fit_trial_last_update,best_urgency_trial_title,best_urgency_trial_status,best_urgency_trial_phases,best_urgency_trial_last_update,recent_job_hits,fit_reason,urgency_reason,urgency_source,access_reason,bonus_recent_trial,bonus_multi_trial,trigger_summary,evidence_links,target_roles,job_hit_keywords,job_hit_titles
1,AstraZeneca,9.10,3.0,3.0,2.0,7,"A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.",RECRUITING,"[""PHASE1"", ""PHASE2""]",2026-02-10,"A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.",RECRUITING,"[""PHASE1"", ""PHASE2""]",2026-02-10,0,trial title indicates T-cell engager / T-cell engaging / T-cell redirecting,"trial status RECRUITING and phase in ['PHASE1', 'PHASE2']",trial,company on watchlist / ATS known,0.5,0.6,"trial_candidate: A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies. | trial_candidate: A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies | trial_candidate: A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation",https://clinicaltrials.gov/study/NCT06542250 ; https://clinicaltrials.gov/study/NCT06564038 ; https://clinicaltrials.gov/study/NCT05877599 ; https://clinicaltrials.gov/study/NCT06218914 ; https://clinicaltrials.gov/study/NCT06005493 ; https://clinicaltrials.gov/study/NCT07215585 ; https://clinicaltrials.gov/study/NCT07201558,"Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development | Clinical Scientist / Early Clinical Development Lead (Phase 1)",[],[]
2,Pfizer,8.10,2.0,3.0,2.0,6,MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide),RECRUITING,"[""PHASE3""]",2026-02-03,A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30),RECRUITING,"[""PHASE1""]",2026-02-05,0,trial title contains CD3,trial status RECRUITING and phase in ['PHASE1'],trial,company on watchlist / ATS known,0.5,0.6,trial_candidate: A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30) | trial_candidate: MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) | trial_candidate: A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments,https://clinicaltrials.gov/study/NCT06215118 ; https://clinicaltrials.gov/study/NCT06152575 ; https://clinicaltrials.gov/study/NCT05020236 ; https://clinicaltrials.gov/study/NCT06057402 ; https://clinicaltrials.gov/study/NCT05090566 ; https://clinicaltrials.gov/study/NCT04649359,"Clinical Scientist / Early Clinical Development Lead (Phase 1) | Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development",[],[]
3,Cullinan Therapeutics Inc.,7.80,3.0,3.0,1.0,3,"A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease",RECRUITING,"[""PHASE1""]",2025-11-19,"A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease",RECRUITING,"[""PHASE1""]",2025-11-19,0,trial title indicates T-cell engager / T-cell engaging / T-cell redirecting,trial status RECRUITING and phase in ['PHASE1'],trial,not on watchlist,0.5,0.3,"trial_candidate: A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease | trial_candidate: A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Rheumatoid Arthritis | trial_candidate: A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL)",https://clinicaltrials.gov/study/NCT07041099 ; https://clinicaltrials.gov/study/NCT06994143 ; https://clinicaltrials.gov/study/NCT05879744,"Clinical Scientist / Early Clinical Development Lead (Phase 1) | Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development",[],[]
4,"TScan Therapeutics, Inc.",7.80,3.0,3.0,1.0,3,A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors,ACTIVE_NOT_RECRUITING,"[""PHASE1""]",2025-11-17,A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors,ACTIVE_NOT_RECRUITING,"[""PHASE1""]",2025-11-17,0,trial title contains CAR-T/TCR-T/chimeric antigen receptor,trial status ACTIVE_NOT_RECRUITING and phase in ['PHASE1'],trial,not on watchlist,0.5,0.3,"trial_candidate: A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors | trial_candidate: A Long Term Follow-up Study of TScan TCR-T Products | trial_candidate: A Study of TSC-100 and TSC-101 in AML, ALL and MDS in Patients Undergoing Allogeneic Peripheral Blood Stem Transplantation",https://clinicaltrials.gov/study/NCT05973487 ; https://clinicaltrials.gov/study/NCT06976736 ; https://clinicaltrials.gov/study/NCT05473910,"Clinical Scientist / Early Clinical Development Lead (Phase 1) | Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development",[],[]
5,"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company",7.65,3.0,3.0,1.0,2,Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma,RECRUITING,"[""PHASE2""]",2026-02-10,Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma,RECRUITING,"[""PHASE2""]",2026-02-10,0,trial title contains CAR-T/TCR-T/chimeric antigen receptor,trial status RECRUITING and phase in ['PHASE2'],trial,not on watchlist,0.5,0.15,"trial_candidate: Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma | trial_candidate: A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma",https://clinicaltrials.gov/study/NCT06297226 ; https://clinicaltrials.gov/study/NCT06121843,"Clinical Scientist / Early Clinical Development Lead (Phase 1) | Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development",[],[]
6,"Hebei Senlang Biotechnology Inc., Ltd.",7.65,3.0,3.0,1.0,2,Phase II Trial of S101 Autologous Anti-CD7 CAR-T Cells in Patients With R/R T-LBL/ALL.,NOT_YET_RECRUITING,"[""PHASE2""]",2025-11-24,Phase II Trial of S101 Autologous Anti-CD7 CAR-T Cells in Patients With R/R T-LBL/ALL.,NOT_YET_RECRUITING,"[""PHASE2""]",2025-11-24,0,trial title contains CAR-T/TCR-T/chimeric antigen receptor,trial status NOT_YET_RECRUITING and phase in ['PHASE2'],trial,not on watchlist,0.5,0.15,trial_candidate: Phase II Trial of S101 Autologous Anti-CD7 CAR-T Cells in Patients With R/R T-LBL/ALL. | trial_candidate: Assessment of Senl_B19 CAR-T Cells in Relapsed/Refractory CD19+ B-ALL,https://clinicaltrials.gov/study/NCT07244380 ; https://clinicaltrials.gov/study/NCT07244406,"Clinical Scientist / Early Clinical Development Lead (Phase 1) | Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development",[],[]
7,"Corregene Biotechnology Co., Ltd",7.65,3.0,3.0,1.0,2,KRAS-Specific Autologous TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors,ACTIVE_NOT_RECRUITING,"[""PHASE1""]",2026-01-30,KRAS-Specific Autologous TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors,ACTIVE_NOT_RECRUITING,"[""PHASE1""]",2026-01-30,0,trial title contains CAR-T/TCR-T/chimeric antigen receptor,trial status ACTIVE_NOT_RECRUITING and phase in ['PHASE1'],trial,not on watchlist,0.5,0.15,trial_candidate: KRAS-Specific Autologous TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors | trial_candidate: CRTE7A2-01 TCR-T Cells for HPV-16 Positive Advanced Cancers,https://clinicaltrials.gov/study/NCT06767046 ; https://clinicaltrials.gov/study/NCT06358053,"Clinical Scientist / Early Clinical Development Lead (Phase 1) | Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development",[],[]
8,Carina Biotech Limited,7.50,3.0,3.0,1.0,1,"A Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Subjects With Metastatic Colorectal Cancer",RECRUITING,"[""PHASE1"", ""PHASE2""]",2026-01-13,"A Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Subjects With Metastatic Colorectal Cancer",RECRUITING,"[""PHASE1"", ""PHASE2""]",2026-01-13,0,trial title contains CAR-T/TCR-T/chimeric antigen receptor,"trial status RECRUITING and phase in ['PHASE1', 'PHASE2']",trial,not on watchlist,0.5,0.0,"trial_candidate: A Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Subjects With Metastatic Colorectal Cancer",https://clinicaltrials.gov/study/NCT05759728,"Clinical Scientist / Early Clinical Development Lead (Phase 1) | Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development",[],[]
9,"Shanghai Ruiliyuan Biotechnology Co., Ltd.",7.50,3.0,3.0,1.0,1,HRYZ-T102 TCR-T Cell for AFP Positive Advanced HCC and Other Solid Tumors,RECRUITING,"[""PHASE1""]",2025-12-02,HRYZ-T102 TCR-T Cell for AFP Positive Advanced HCC and Other Solid Tumors,RECRUITING,"[""PHASE1""]",2025-12-02,0,trial title contains CAR-T/TCR-T/chimeric antigen receptor,trial status RECRUITING and phase in ['PHASE1'],trial,not on watchlist,0.5,0.0,trial_candidate: HRYZ-T102 TCR-T Cell for AFP Positive Advanced HCC and Other Solid Tumors,https://clinicaltrials.gov/study/NCT06515314,"Clinical Scientist / Early Clinical Development Lead (Phase 1) | Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development",[],[]
10,Lion TCR Pte. Ltd.,7.30,3.0,3.0,1.0,3,Autologous HBV-TCR T Cell Therapy (LioCyx-M) for the Treatment of Hepatocellular Carcinoma,RECRUITING,"[""PHASE1""]",2025-05-08,Autologous HBV-TCR T Cell Therapy (LioCyx-M) for the Treatment of Hepatocellular Carcinoma,RECRUITING,"[""PHASE1""]",2025-05-08,0,trial title contains CAR-T/TCR-T/chimeric antigen receptor,trial status RECRUITING and phase in ['PHASE1'],trial,not on watchlist,0.0,0.3,trial_candidate: Autologous HBV-TCR T Cell Therapy (LioCyx-M) for the Treatment of Hepatocellular Carcinoma | trial_candidate: Study of HBV-TCR T Cells (LioCyx-M) as Monotherapy or as Combination With Lenvatinib for HBV-related HCC | trial_candidate: Redirected HBV-Specific T Cells in Patients With HBV-related HCC (SAFE-T-HBV),https://clinicaltrials.gov/study/NCT06961617 ; https://clinicaltrials.gov/study/NCT05195294 ; https://clinicaltrials.gov/study/NCT04745403,"Clinical Scientist / Early Clinical Development Lead (Phase 1) | Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development",[],[]
11,SCG Cell Therapy Pte. Ltd.,7.30,3.0,3.0,1.0,3,A Study of SCG101 TCR-T Cell Therpay in the Treatment of Subjects With Hepatitis B Virus-Related,RECRUITING,"[""PHASE1""]",2024-09-27,A Study of SCG101 in the Treatment of Subjects With Hepatitis B Virus-Related Hepatocellular Carcinoma,RECRUITING,"[""PHASE1"", ""PHASE2""]",2025-02-18,0,trial title contains CAR-T/TCR-T/chimeric antigen receptor,"trial status RECRUITING and phase in ['PHASE1', 'PHASE2']",trial,not on watchlist,0.0,0.3,trial_candidate: A Study of SCG101 in the Treatment of Subjects With Hepatitis B Virus-Related Hepatocellular Carcinoma | trial_candidate: A Study of SCG101 TCR-T Cell Therpay in the Treatment of Subjects With Hepatitis B Virus-Related | trial_candidate: Phase 1/2 Study of Autologous SCG142 TCR T Cells in Patients With HPV16/52-positive Carcinoma,https://clinicaltrials.gov/study/NCT05417932 ; https://clinicaltrials.gov/study/NCT06617000 ; https://clinicaltrials.gov/study/NCT06505551,"Clinical Scientist / Early Clinical Development Lead (Phase 1) | Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development",[],[]
12,"Guangzhou FineImmune Biotechnology Co., LTD.",7.15,3.0,3.0,1.0,2,"An Open-label, Phase I Clinical Trial of Super1 TCR-T in NY-ESO-1-positive Patients With Advanced Solid Tumors",RECRUITING,"[""PHASE1""]",2025-09-03,"An Open-label, Phase I Clinical Trial of Super1 TCR-T in NY-ESO-1-positive Patients With Advanced Solid Tumors",RECRUITING,"[""PHASE1""]",2025-09-03,0,trial title contains CAR-T/TCR-T/chimeric antigen receptor,trial status RECRUITING and phase in ['PHASE1'],trial,not on watchlist,0.0,0.15,"trial_candidate: An Open-label, Phase I Clinical Trial of Super1 TCR-T in NY-ESO-1-positive Patients With Advanced Solid Tumors | trial_candidate: Individualized Tumor Specific TCR- T Cells in the Treatment of Advanced Solid Tumors",https://clinicaltrials.gov/study/NCT06942143 ; https://clinicaltrials.gov/study/NCT03891706,"Clinical Scientist / Early Clinical Development Lead (Phase 1) | Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development",[],[]
13,Beijing Yongtai Ruike Biotechnology Company Ltd,7.00,3.0,3.0,1.0,1,CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALL,RECRUITING,"[""PHASE2""]",2025-01-13,CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALL,RECRUITING,"[""PHASE2""]",2025-01-13,0,trial title contains CAR-T/TCR-T/chimeric antigen receptor,trial status RECRUITING and phase in ['PHASE2'],trial,not on watchlist,0.0,0.0,trial_candidate: CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALL,https://clinicaltrials.gov/study/NCT06179524,"Clinical Scientist / Early Clinical Development Lead (Phase 1) | Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development",[],[]
14,"Nkarta, Inc.",7.00,3.0,3.0,1.0,1,"NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers",ACTIVE_NOT_RECRUITING,"[""PHASE1""]",2024-12-24,"NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers",ACTIVE_NOT_RECRUITING,"[""PHASE1""]",2024-12-24,0,trial title contains CAR-T/TCR-T/chimeric antigen receptor,trial status ACTIVE_NOT_RECRUITING and phase in ['PHASE1'],trial,not on watchlist,0.0,0.0,"trial_candidate: NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers",https://clinicaltrials.gov/study/NCT05020678,"Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development | Clinical Scientist / Early Clinical Development Lead (Phase 1)",[],[]
15,TCRCure Biopharma Ltd.,7.00,3.0,3.0,1.0,1,NY-ESO-1 TCR-T Cells for NY-ESO-1 Positive Subjects With Advanced Solid Tumors,RECRUITING,"[""PHASE1""]",2025-07-16,NY-ESO-1 TCR-T Cells for NY-ESO-1 Positive Subjects With Advanced Solid Tumors,RECRUITING,"[""PHASE1""]",2025-07-16,0,trial title contains CAR-T/TCR-T/chimeric antigen receptor,trial status RECRUITING and phase in ['PHASE1'],trial,not on watchlist,0.0,0.0,trial_candidate: NY-ESO-1 TCR-T Cells for NY-ESO-1 Positive Subjects With Advanced Solid Tumors,https://clinicaltrials.gov/study/NCT05881525,"Clinical Scientist / Early Clinical Development Lead (Phase 1) | Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development",[],[]
16,Bioray Laboratories,6.65,3.0,2.0,1.0,2,Universal CAR-T Cell Therapy for NHL,RECRUITING,"[""NA""]",2025-11-25,Universal CAR-T Cell Therapy for NHL,RECRUITING,"[""NA""]",2025-11-25,0,trial title contains CAR-T/TCR-T/chimeric antigen receptor,trial status RECRUITING,trial,not on watchlist,0.5,0.15,trial_candidate: Universal CAR-T Cell Therapy for NHL | trial_candidate: Universal CAR-T Cell Therapy for Refractory Lupus Nephritis,https://clinicaltrials.gov/study/NCT07248163 ; https://clinicaltrials.gov/study/NCT06681337,"Clinical Scientist / Early Clinical Development Lead (Phase 1) | Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development",[],[]
17,Galapagos NV,6.50,3.0,2.0,1.0,1,Long-term Follow-up of Participants Treated With Galapagos Chimeric Antigen Receptor (CAR) T-cell Therapies,RECRUITING,"[""PHASE3""]",2026-02-05,Long-term Follow-up of Participants Treated With Galapagos Chimeric Antigen Receptor (CAR) T-cell Therapies,RECRUITING,"[""PHASE3""]",2026-02-05,0,trial title contains CAR-T/TCR-T/chimeric antigen receptor,trial status RECRUITING,trial,not on watchlist,0.5,0.0,trial_candidate: Long-term Follow-up of Participants Treated With Galapagos Chimeric Antigen Receptor (CAR) T-cell Therapies,https://clinicaltrials.gov/study/NCT06652633,"Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development | Clinical Scientist / Early Clinical Development Lead (Phase 1)",[],[]
18,Regeneron Pharmaceuticals,6.10,1.0,3.0,1.0,12,"A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment",RECRUITING,"[""PHASE1"", ""PHASE2""]",2026-02-06,"A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment",RECRUITING,"[""PHASE1"", ""PHASE2""]",2026-02-06,0,no strong wedge keywords in trial titles,"trial status RECRUITING and phase in ['PHASE1', 'PHASE2']",trial,not on watchlist,0.5,0.6,"trial_candidate: A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment | trial_candidate: A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma | trial_candidate: A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma",https://clinicaltrials.gov/study/NCT05828511 ; https://clinicaltrials.gov/study/NCT06097364 ; https://clinicaltrials.gov/study/NCT06149286 ; https://clinicaltrials.gov/study/NCT06091865 ; https://clinicaltrials.gov/study/NCT06469281 ; https://clinicaltrials.gov/study/NCT05730036 ; https://clinicaltrials.gov/study/NCT06787612 ; https://clinicaltrials.gov/study/NCT07222761,"Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development | Clinical Scientist / Early Clinical Development Lead (Phase 1)",[],[]
19,"Guangzhou Bio-gene Technology Co., Ltd",6.00,3.0,2.0,1.0,1,BCMA/GPRC5D CAR-T Therapy for Multiple Myeloma,NOT_YET_RECRUITING,"[""EARLY_PHASE1""]",2025-09-29,BCMA/GPRC5D CAR-T Therapy for Multiple Myeloma,NOT_YET_RECRUITING,"[""EARLY_PHASE1""]",2025-09-29,0,trial title contains CAR-T/TCR-T/chimeric antigen receptor,trial status NOT_YET_RECRUITING,trial,not on watchlist,0.0,0.0,trial_candidate: BCMA/GPRC5D CAR-T Therapy for Multiple Myeloma,https://clinicaltrials.gov/study/NCT07196124,"Clinical Scientist / Early Clinical Development Lead (Phase 1) | Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development",[],[]
20,"Shanghai Cell Therapy Group Co.,Ltd",6.00,3.0,2.0,1.0,1,An Exploratory Study on the Treatment of Advanced Solid Tumors by Fast CAR T Cells,RECRUITING,"[""EARLY_PHASE1""]",2024-02-08,An Exploratory Study on the Treatment of Advanced Solid Tumors by Fast CAR T Cells,RECRUITING,"[""EARLY_PHASE1""]",2024-02-08,0,trial title contains CAR-T/TCR-T/chimeric antigen receptor,trial status RECRUITING,trial,not on watchlist,0.0,0.0,trial_candidate: An Exploratory Study on the Treatment of Advanced Solid Tumors by Fast CAR T Cells,https://clinicaltrials.gov/study/NCT06249256,"Clinical Scientist / Early Clinical Development Lead (Phase 1) | Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development",[],[]
21,A2 Biotherapeutics Inc.,6.00,3.0,2.0,1.0,1,Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing,RECRUITING,[],2025-11-03,Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing,RECRUITING,[],2025-11-03,0,trial title contains CAR-T/TCR-T/chimeric antigen receptor,trial status RECRUITING,trial,not on watchlist,0.0,0.0,trial_candidate: Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing,https://clinicaltrials.gov/study/NCT04981119,"Clinical Scientist / Early Clinical Development Lead (Phase 1) | Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development",[],[]
22,Carbiogene Therapeutics Co. Ltd.,6.00,3.0,2.0,1.0,1,Clinical Study of Anti-ILT3 CAR-T Therapy for R/R AML(M4/M5),RECRUITING,"[""EARLY_PHASE1""]",2021-03-23,Clinical Study of Anti-ILT3 CAR-T Therapy for R/R AML(M4/M5),RECRUITING,"[""EARLY_PHASE1""]",2021-03-23,0,trial title contains CAR-T/TCR-T/chimeric antigen receptor,trial status RECRUITING,trial,not on watchlist,0.0,0.0,trial_candidate: Clinical Study of Anti-ILT3 CAR-T Therapy for R/R AML(M4/M5),https://clinicaltrials.gov/study/NCT04803929,"Clinical Scientist / Early Clinical Development Lead (Phase 1) | Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development",[],[]
23,"Shanghai First Song Biotechnology Co., LTD",6.00,3.0,2.0,1.0,1,Safety and Efficacy of Anti-CD20/CD30 CAR-T Cells in Subjects with Relapsed/Refractory Lymphoma,RECRUITING,"[""EARLY_PHASE1""]",2024-09-19,Safety and Efficacy of Anti-CD20/CD30 CAR-T Cells in Subjects with Relapsed/Refractory Lymphoma,RECRUITING,"[""EARLY_PHASE1""]",2024-09-19,0,trial title contains CAR-T/TCR-T/chimeric antigen receptor,trial status RECRUITING,trial,not on watchlist,0.0,0.0,trial_candidate: Safety and Efficacy of Anti-CD20/CD30 CAR-T Cells in Subjects with Relapsed/Refractory Lymphoma,https://clinicaltrials.gov/study/NCT06532643,"Clinical Scientist / Early Clinical Development Lead (Phase 1) | Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development",[],[]
24,Excyte Biopharma Ltd,5.95,1.0,3.0,1.0,4,"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK012",RECRUITING,"[""PHASE1""]",2026-02-05,"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK012",RECRUITING,"[""PHASE1""]",2026-02-05,0,no strong wedge keywords in trial titles,trial status RECRUITING and phase in ['PHASE1'],trial,not on watchlist,0.5,0.44999999999999996,"trial_candidate: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK012 | trial_candidate: Study of YK012 in Moderate to Severe Systemic Lupus Erythematosus | trial_candidate: A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma",https://clinicaltrials.gov/study/NCT06565689 ; https://clinicaltrials.gov/study/NCT07010835 ; https://clinicaltrials.gov/study/NCT06574568 ; https://clinicaltrials.gov/study/NCT06982729,"Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development | Clinical Scientist / Early Clinical Development Lead (Phase 1)",[],[]
25,"Janssen Research & Development, LLC",5.80,1.0,3.0,1.0,3,A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel,RECRUITING,"[""PHASE4""]",2026-01-16,Dose Escalation Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma,ACTIVE_NOT_RECRUITING,"[""PHASE1""]",2026-01-16,0,no strong wedge keywords in trial titles,trial status ACTIVE_NOT_RECRUITING and phase in ['PHASE1'],trial,not on watchlist,0.5,0.3,trial_candidate: A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel | trial_candidate: Dose Escalation Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma | trial_candidate: A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma,https://clinicaltrials.gov/study/NCT05201781 ; https://clinicaltrials.gov/study/NCT03399799 ; https://clinicaltrials.gov/study/NCT04634552,"Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development | Clinical Scientist / Early Clinical Development Lead (Phase 1)",[],[]
26,Genmab,5.80,1.0,3.0,1.0,3,Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma,ACTIVE_NOT_RECRUITING,"[""PHASE2""]",2026-02-04,Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma,ACTIVE_NOT_RECRUITING,"[""PHASE2""]",2026-02-04,0,no strong wedge keywords in trial titles,trial status ACTIVE_NOT_RECRUITING and phase in ['PHASE2'],trial,not on watchlist,0.5,0.3,trial_candidate: Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma | trial_candidate: GEN1047 for Solid Tumors - First in Human (FIH) Trial | trial_candidate: Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome,https://clinicaltrials.gov/study/NCT05660967 ; https://clinicaltrials.gov/study/NCT05180474 ; https://clinicaltrials.gov/study/NCT04623541,"Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development | Clinical Scientist / Early Clinical Development Lead (Phase 1)",[],[]
27,Amgen,5.80,1.0,3.0,1.0,3,"Evaluation of Xaluritamig in High-Risk, Biochemically Recurrent, Non-metastatic Castrate-sensitive Prostate Cancer",ACTIVE_NOT_RECRUITING,"[""PHASE1""]",2026-01-26,"Evaluation of Xaluritamig in High-Risk, Biochemically Recurrent, Non-metastatic Castrate-sensitive Prostate Cancer",ACTIVE_NOT_RECRUITING,"[""PHASE1""]",2026-01-26,0,no strong wedge keywords in trial titles,trial status ACTIVE_NOT_RECRUITING and phase in ['PHASE1'],trial,not on watchlist,0.5,0.3,"trial_candidate: Evaluation of Xaluritamig in High-Risk, Biochemically Recurrent, Non-metastatic Castrate-sensitive Prostate Cancer | trial_candidate: Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer | trial_candidate: Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer",https://clinicaltrials.gov/study/NCT06555796 ; https://clinicaltrials.gov/study/NCT04221542 ; https://clinicaltrials.gov/study/NCT06613100,"Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development | Clinical Scientist / Early Clinical Development Lead (Phase 1)",[],[]
28,Miltenyi Biomedicine GmbH,5.65,1.0,3.0,1.0,2,MB-dNPM1-TCR.1 in Relapsed/Refractory AML,RECRUITING,"[""PHASE1"", ""PHASE2""]",2025-12-23,MB-dNPM1-TCR.1 in Relapsed/Refractory AML,RECRUITING,"[""PHASE1"", ""PHASE2""]",2025-12-23,0,no strong wedge keywords in trial titles,"trial status RECRUITING and phase in ['PHASE1', 'PHASE2']",trial,not on watchlist,0.5,0.15,trial_candidate: MB-dNPM1-TCR.1 in Relapsed/Refractory AML | trial_candidate: MB-CART19.1 r/r CD19+ B-cell Malignancies (BCM),https://clinicaltrials.gov/study/NCT06424340 ; https://clinicaltrials.gov/study/NCT03853616,"Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development | Clinical Scientist / Early Clinical Development Lead (Phase 1)",[],[]
29,Takeda,5.65,1.0,3.0,1.0,2,"A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma",RECRUITING,"[""PHASE3""]",2026-02-10,A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL),ACTIVE_NOT_RECRUITING,"[""PHASE2""]",2025-08-12,0,no strong wedge keywords in trial titles,trial status ACTIVE_NOT_RECRUITING and phase in ['PHASE2'],trial,not on watchlist,0.5,0.15,"trial_candidate: A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma | trial_candidate: A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)",https://clinicaltrials.gov/study/NCT06980480 ; https://clinicaltrials.gov/study/NCT05020015,"Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development | Clinical Scientist / Early Clinical Development Lead (Phase 1)",[],[]
30,Immunocore Ltd,5.65,1.0,3.0,1.0,2,Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers,RECRUITING,"[""PHASE1"", ""PHASE2""]",2026-01-28,Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers,RECRUITING,"[""PHASE1"", ""PHASE2""]",2026-01-28,0,no strong wedge keywords in trial titles,"trial status RECRUITING and phase in ['PHASE1', 'PHASE2']",trial,not on watchlist,0.5,0.15,trial_candidate: Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers | trial_candidate: Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma,https://clinicaltrials.gov/study/NCT06840119 ; https://clinicaltrials.gov/study/NCT03070392,"Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development | Clinical Scientist / Early Clinical Development Lead (Phase 1)",[],[]
31,Boehringer Ingelheim,5.65,1.0,3.0,1.0,2,DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers,RECRUITING,"[""PHASE2""]",2026-02-06,DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers,RECRUITING,"[""PHASE2""]",2026-02-06,0,no strong wedge keywords in trial titles,trial status RECRUITING and phase in ['PHASE2'],trial,not on watchlist,0.5,0.15,trial_candidate: DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers | trial_candidate: A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With a Tumour in the Brain That is Positive for DLL3,https://clinicaltrials.gov/study/NCT05882058 ; https://clinicaltrials.gov/study/NCT05916313,"Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development | Clinical Scientist / Early Clinical Development Lead (Phase 1)",[],[]
32,"Arsenal Biosciences, Inc.",5.50,1.0,3.0,1.0,1,"AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)",RECRUITING,"[""PHASE1"", ""PHASE2""]",2026-01-12,"AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)",RECRUITING,"[""PHASE1"", ""PHASE2""]",2026-01-12,0,no strong wedge keywords in trial titles,"trial status RECRUITING and phase in ['PHASE1', 'PHASE2']",trial,not on watchlist,0.5,0.0,"trial_candidate: AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)",https://clinicaltrials.gov/study/NCT07285694,"Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development | Clinical Scientist / Early Clinical Development Lead (Phase 1)",[],[]
33,Cabaletta Bio,5.50,1.0,3.0,1.0,1,RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis,RECRUITING,"[""PHASE1"", ""PHASE2""]",2026-01-15,RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis,RECRUITING,"[""PHASE1"", ""PHASE2""]",2026-01-15,0,no strong wedge keywords in trial titles,"trial status RECRUITING and phase in ['PHASE1', 'PHASE2']",trial,not on watchlist,0.5,0.0,trial_candidate: RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis,https://clinicaltrials.gov/study/NCT06359041,"Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development | Clinical Scientist / Early Clinical Development Lead (Phase 1)",[],[]
34,Fate Therapeutics,5.50,1.0,3.0,1.0,1,A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease,RECRUITING,"[""PHASE1""]",2026-01-28,A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease,RECRUITING,"[""PHASE1""]",2026-01-28,0,no strong wedge keywords in trial titles,trial status RECRUITING and phase in ['PHASE1'],trial,not on watchlist,0.5,0.0,trial_candidate: A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease,https://clinicaltrials.gov/study/NCT06308978,"Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development | Clinical Scientist / Early Clinical Development Lead (Phase 1)",[],[]
35,Novartis Pharmaceuticals,5.50,1.0,3.0,1.0,1,"Open-label, Multi-center, Phase I/II Study to Assess Safety, Disease Progression and Cellular Kinetics Following YTB323 Administration in Participants With Non-active Progressive Multiple Sclerosis (PMS)",RECRUITING,"[""PHASE1"", ""PHASE2""]",2025-11-20,"Open-label, Multi-center, Phase I/II Study to Assess Safety, Disease Progression and Cellular Kinetics Following YTB323 Administration in Participants With Non-active Progressive Multiple Sclerosis (PMS)",RECRUITING,"[""PHASE1"", ""PHASE2""]",2025-11-20,0,no strong wedge keywords in trial titles,"trial status RECRUITING and phase in ['PHASE1', 'PHASE2']",trial,not on watchlist,0.5,0.0,"trial_candidate: Open-label, Multi-center, Phase I/II Study to Assess Safety, Disease Progression and Cellular Kinetics Following YTB323 Administration in Participants With Non-active Progressive Multiple Sclerosis (PMS)",https://clinicaltrials.gov/study/NCT06675864,"Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development | Clinical Scientist / Early Clinical Development Lead (Phase 1)",[],[]
36,AbbVie,5.50,1.0,3.0,1.0,1,A Study of TNB-383B in Participants With Relapsed or Refractory Multiple Myeloma,ACTIVE_NOT_RECRUITING,"[""PHASE1"", ""PHASE2""]",2026-02-06,A Study of TNB-383B in Participants With Relapsed or Refractory Multiple Myeloma,ACTIVE_NOT_RECRUITING,"[""PHASE1"", ""PHASE2""]",2026-02-06,0,no strong wedge keywords in trial titles,"trial status ACTIVE_NOT_RECRUITING and phase in ['PHASE1', 'PHASE2']",trial,not on watchlist,0.5,0.0,trial_candidate: A Study of TNB-383B in Participants With Relapsed or Refractory Multiple Myeloma | trial_collaborator: Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma | trial_collaborator: Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome,https://clinicaltrials.gov/study/NCT03933735 ; https://clinicaltrials.gov/study/NCT05660967 ; https://clinicaltrials.gov/study/NCT04623541,"Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development | Clinical Scientist / Early Clinical Development Lead (Phase 1)",[],[]
37,Eli Lilly and Company,5.50,1.0,3.0,1.0,1,A Study of LY4152199 in Participants With Previously Treated B-cell Cancers (BAF_FRontier-1 ),NOT_YET_RECRUITING,"[""PHASE1""]",2026-02-10,A Study of LY4152199 in Participants With Previously Treated B-cell Cancers (BAF_FRontier-1 ),NOT_YET_RECRUITING,"[""PHASE1""]",2026-02-10,0,no strong wedge keywords in trial titles,trial status NOT_YET_RECRUITING and phase in ['PHASE1'],trial,not on watchlist,0.5,0.0,trial_candidate: A Study of LY4152199 in Participants With Previously Treated B-cell Cancers (BAF_FRontier-1 ) | trial_collaborator: Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome,https://clinicaltrials.gov/study/NCT07101328 ; https://clinicaltrials.gov/study/NCT04623541,"Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development | Clinical Scientist / Early Clinical Development Lead (Phase 1)",[],[]
38,"Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",5.50,1.0,3.0,1.0,1,A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001),ACTIVE_NOT_RECRUITING,"[""PHASE1"", ""PHASE2""]",2026-02-02,A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001),ACTIVE_NOT_RECRUITING,"[""PHASE1"", ""PHASE2""]",2026-02-02,0,no strong wedge keywords in trial titles,"trial status ACTIVE_NOT_RECRUITING and phase in ['PHASE1', 'PHASE2']",trial,not on watchlist,0.5,0.0,trial_candidate: A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001),https://clinicaltrials.gov/study/NCT04471727,"Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development | Clinical Scientist / Early Clinical Development Lead (Phase 1)",[],[]
39,Keymed Biosciences Co.Ltd,5.50,1.0,3.0,1.0,1,A Study of CM336 in Patients With Relapsed or Refractory Autoimmune Cytopenia,RECRUITING,"[""PHASE1"", ""PHASE2""]",2025-12-17,A Study of CM336 in Patients With Relapsed or Refractory Autoimmune Cytopenia,RECRUITING,"[""PHASE1"", ""PHASE2""]",2025-12-17,0,no strong wedge keywords in trial titles,"trial status RECRUITING and phase in ['PHASE1', 'PHASE2']",trial,not on watchlist,0.5,0.0,trial_candidate: A Study of CM336 in Patients With Relapsed or Refractory Autoimmune Cytopenia,https://clinicaltrials.gov/study/NCT07175493,"Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development | Clinical Scientist / Early Clinical Development Lead (Phase 1)",[],[]
40,Ouro Medicines,5.50,1.0,3.0,1.0,1,OM336 in Seropositive Autoimmune Diseases,NOT_YET_RECRUITING,"[""PHASE1""]",2025-11-14,OM336 in Seropositive Autoimmune Diseases,NOT_YET_RECRUITING,"[""PHASE1""]",2025-11-14,0,no strong wedge keywords in trial titles,trial status NOT_YET_RECRUITING and phase in ['PHASE1'],trial,not on watchlist,0.5,0.0,trial_candidate: OM336 in Seropositive Autoimmune Diseases,https://clinicaltrials.gov/study/NCT07229144,"Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development | Clinical Scientist / Early Clinical Development Lead (Phase 1)",[],[]
